Kalorama: Market For Testing On Tissues and Cells Reaches 7.5 Billion-Dollars
NEW YORK, Dec. 18, 2014 /PRNewswire/ -- Driven by new technologies and the need to discover biomarkers, the tissue and cell-based diagnostic market grew to an estimated 7.4 billion in revenues in 2013 for in vitro diagnostic (IVD) and other reagents used by clinical laboratories, according to Kalorama Information. The once field is increasingly automated and many new technologies are now being applied in this field, including mass spectrometry, DNA sequencing, circulating tumor cells, and others. The estimate was made in Kalorama's recent report, The World Market for Tissue Diagnostics and Cell-Based Diagnostics.
"Growth in the tissue and cell diagnostics market is being driven by research to better understand the biological mechanisms and processes of cancer," said Bruce Carlson, publisher of Kalorama information. "Biopsy samples are the most common and effective in this area."
Growth is also driven by development of new targeted therapies based on outcomes of this research, according to the report. The study of tissues and cells is an important part of life science research, Kalorama says, as scientists work to understand the role of proteins and other molecules. All of the technologies and assays currently being used in clinical laboratories plus new, emerging technologies such as DNA sequencing and mass spectrometry, are being studied by life science researchers. They are also an important part of drug discovery and development as cell-based assays have important roles in research, and also in preclinical toxicology and other studies, in drug development.
The Pharmaceutical Research and Manufacturers of America (PhRMA) reports that nearly 800 new medicines and vaccines are in clinical testing for cancer. While these new therapies represent a wide range of different approaches, they include new targeted therapies. A March 2014 press release from IMS Health reported that 22 new oncology therapies has been launched in the previous two years. The American Cancer Society reports that about 1,665,540 new cancer cases are expected to be diagnosed in 2014.
The report, The World Market for Tissue Diagnostics and Cell-Based Diagnostics, contains more trends in the histology and cytology test industries, including breakouts of important segments in cytology and histology testing, as well as profiling scores of companies in the market. Geographic breakdowns of the market are also provided. The report can be obtained at http://www.kaloramainformation.com/Tissue-Cell-Based-8540184/.
About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20140801/132634
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kalorama-market-for-testing-on-tissues-and-cells-reaches-75-billion-dollars-300009956.html
SOURCE Kalorama Information
Share this article